Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Enrolling By Invitation NCT05883748

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

Conditions: Erythropoietic Protoporphyria

Sex: All

Ages: 12 Years – N/A

Healthy volunteers: No

Phase: PHASE2, PHASE3

Enrollment: 230

Sponsor: Disc Medicine, Inc

Location: University of Alabama Hospital Birmingham Alabama

Summary

This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.

Eligibility Criteria

Inclusion Criteria: * Participants with diagnosis of EPP who are participating (or who have participated) in a prior Disc Medicine bitopertin study and who have completed the randomized treatment phase and End-of-Study visit * Aged ≥12 years upon study consent * Body weight ≥32 kg for participants \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05883748). StuddyBuddy aggregates publicly available trial information.